Study Evaluating Pneumococcal Meningitis in the Paediatric Population in

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

The aim of this study is to determine the prevalence of pneumococcal meningitis in the paediatric population in Spain four years after the marketing of Prevenar. Also secondary objectives are: 1) to determine the clinical characteristics and outcome of the disease; and 2) to determine serotypes and antibiotic resistance patterns.

See also
Status	Clinical Trial	Phase
Terminated	`NCT01478035` - Study on the Efficacy of Phenytoin in the Prophylaxis of Seizures of Patients With Pneumococcal Meningitis at Least 50 Yrs Old.	Phase 4
Recruiting	`NCT03480191` - Adjunction of Daptomycin for the Treatment of Pneumococcal Meningitis	Phase 2
Completed	`NCT00162578` - Vancomycin Concentration in Cerebrospinal Fluid During Pneumococcal Meningitis	N/A

NCT number	NCT00227214
Study type	Observational
Source	Wyeth is now a wholly owned subsidiary of Pfizer
Contact
Status	Completed
Phase	N/A
Start date	January 2004
Completion date	December 2006

Study Evaluating Pneumococcal Meningitis in the Paediatric Population in Spain Four Years After the Marketing of Prevenar.

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms